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Background and objectives: Cinacalcet, a novel calcimimetic, targets the calcium-sensing receptor to lower parathyroid hormone
(PTH), calcium, and phosphorus levels in dialysis patients with secondary hyperparathyroidism (SHPT). This study compared the
efficacy of a cinacalcet-based regimen with unrestricted conventional care (vitamin D and phosphate binders) for achieving the
stringent National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) targets for dialysis patients.
Study design: In this multicenter, open-label study, hemodialysis patients with poorly controlled SHPT were randomized to
receive conventional care (n  184) or a cinacalcet-based regimen (n  368). Doses of cinacalcet, vitamin D sterols, and phosphate
binders were adjusted during a 16-wk dose-optimization phase with the use of algorithms that allowed cinacalcet to be used with
adjusted doses of vitaminD. The primary end point was the proportion of patients withmean intact PTH<300 pg/ml during a 7-wk
efficacy assessment phase.
Results: A higher proportion of patients receiving the cinacalcet-based regimen versus conventional care achieved the targets for
PTH (71% versus 22%, respectively; P < 0.001), Ca  P (77% versus 58%, respectively; P < 0.001), calcium (76% versus 33%,
respectively; P< 0.001), phosphorus (63% versus 50%, respectively; P 0.002), and PTH and Ca P (59% versus 16%, respectively,
P < 0.001), and allowed a 22% reduction in vitamin D dosage in patients receiving vitamin D at baseline. Achievement of targets
was greatest in patients with less severe disease (intact PTH range, 300 to 500 pg/ml) and the cinacalcet dose required was lower in
these patients (median  30 mg/d).
Conclusions: Compared with conventional therapy, a cinacalcet-based treatment algorithm increased achievement of KDOQI
treatment targets in dialysis patients in whom conventional therapy was no longer effective in controlling this disease.
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S econdary hyperparathyroidism (SHPT), characterizedby parathyroid hyperplasia and persistently elevatedplasma levels of parathyroid hormone (PTH), com-
monly accompanies chronic kidney disease (CKD) (1–4). A
major complication of SHPT is renal osteodystrophy, whereas
alterations in calcium and phosphorus metabolism additionally
contribute to soft tissue calcification (including cardiovascular
calcification) (5–7). Elevated serum levels of PTH, phosphorus,
and calcium  phosphorus ion product (Ca  P) are associated
with an increased mortality risk (8–11). In recognition of this,
the National Kidney Foundation Kidney Disease Outcome
Quality Initiative (KDOQI) has published treatment goals for
these patients (12).
Conventional treatment for SHPT includes calcium supple-
mentation, dietary phosphate restriction, oral phosphate-bind-
ing agents, active vitamin D sterols, and parathyroidectomy in
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patients refractory to therapy (13). Calcium supplement and
calcium-containing phosphate binder use, however, induce hy-
percalcemia, particularly when administered concomitantly
with vitamin D, which increases intestinal absorption of cal-
cium and phosphorus. A significant proportion of hemodialysis
patients receiving such treatment have elevated calcium and
phosphorus, potentially requiring interruption of treatment
that allows disease progression (8,13–15). Even in patients
treated with paracalcitol that may have reduced capacity to
enhance intestinal absorption of calcium and phosphorus,
60% experienced calcium levels 11 mg/dl and/or Ca  P
75 mg2/dl2 (16–18). Consequently, achievement of KDOQI
treatment goals is difficult with conventional treatment and
novel treatment strategies are required.
The calcimimetics have provided an alternative approach to
the treatment of SHPT by directly targeting the calcium-sensing
receptor (CaR) on the parathyroid cell surface that regulates the
secretion of PTH. These agents increase the extracelluar calcium
sensitivity of the CaR to lower circulating PTH levels within 1
to 2 h of administration (19–22). Cinacalcet (Sensipar/Mim-
para, Amgen Inc., Thousand Oaks, CA) has been shown to
significantly reduce PTH levels in dialysis patients with poorly
controlled SHPT when added to conventional treatment regi-
mens while simultaneously bringing about a reduction in se-
rum calcium, phosphorus, and Ca  P (23–26).
Administration of vitamin D sterols in most previously re-
ported studies of cinacalcet was kept relatively constant to
isolate the effect of cinacalcet (24–26). In the OPTIMA (Open-
Label, Randomized Study Using Cinacalcet to Improve
Achievement of KDOQI Targets in Patients with End-Stage
Renal Disease) study, we compared a new treatment algorithm
using cinacalcet and optimized doses of vitamin D, with the use
of conventional therapy, to achieve KDOQI treatment goals for
serum PTH, Ca  P, calcium, and phosphorus in patients with
uncontrolled SHPT.
Patients and Methods
Patients
Patients were 18 yr of age with end-stage renal disease with SHPT
and had required maintenance dialysis for 1 mo. Eligibility criteria
included intact PTH (iPTH) 300 pg/ml and 800 pg/ml (bio-intact
PTH (biPTH) 150 pg/ml and 410 pg/ml) and albumin-corrected
serum calcium 8.4 mg/dl.
Patients were excluded from the study if they had any unstable
medical condition, were breastfeeding, had experienced a myocardial
infarction within 3 mo of study day 1, had undergone a parathyroid-
ectomy within 6 mo of study day 1, or had a gastrointestinal disorder
associated with impaired absorption of oral medications or an inability
to swallow tablets. Patients who received vitamin D therapy for 21 d
or had a change in their prescribed vitamin D brand or dose within 21 d
before study day 1 were also excluded. Finally, patients who were
enrolled in other studies or had previously enrolled or participated in
other cinacalcet clinical trials were excluded.
The study adhered to the principles of the Declaration of Helsinki.
The independent ethics committee for each study site approved the
study protocol, and all patients provided written informed consent
before the initiation of study-specific procedures.
Study Design
This open-label study consisted of three phases: a maximum 21-d
screening phase, a 16-wk dose-optimization phase, and a 7-wk efficacy-
assessment phase. Patients were stratified by baseline serum Ca  P
(55 or 55 mg2/dl2) and baseline vitamin D use and randomly
assigned in a 2:1 ratio to receive either cinacalcet or conventional care
(vitamin D and phosphate binders). For those randomized to receive
conventional care, investigators were permitted flexibility to modify
their treatment in an attempt to achieve KDOQI targets for PTH,
Ca  P, serum calcium and phosphorus (12), with no specific criteria
for increasing vitamin D dosing. Patients randomized to cinacalcet
treatment were assessed at 2-wk intervals up to week 20 throughout
the dose-optimization and efficacy-assessment phases, and treat-
ment was adjusted according to the OPTIMA treatment algorithm
(Figure 1). A patient’s cinacalcet dose could be increased from a
starting dose of 30 mg once daily to the next sequential daily dose in
the series 30, 60, 90, 120, and 180 mg if their iPTH level was
300 pg/ml (biPTH 150 pg/ml) at the previous study visit, unless
albuinin corrected serum calcium was 8.0 mg/dl or an adverse
event precluded dose increase. The cinacalcet dose was to be re-
duced to the next lowest dose level if a patient’s iPTH level was
150 pg/ml (biPTH 75 pg/ml) for two consecutive study visits
and they were not receiving a vitamin D sterol, or this could not be
further reduced.
After cinacalcet initiation, the dosage of any prescribed vitamin D
sterol was optimized according to the treatment algorithm to achieve
serum PTH, calcium, and phosphorus targets. When indicated (PTH
150 pg/ml and/or calcium and phosphorus exceeded KDOQI target
levels), the dose of a vitamin D sterol was reduced by approximately
50%, in sequential steps, until a minimum dose (intravenous calcitriol,
0.5 g three times per week (TIW); intravenous alfacalcidol, 1 g TIW;
intravenous paracalcitol, 2 g TIW; oral calcitriol, 0.25 g TIW; oral
alfacalcidol, 0.25 g/d) was reached. The vitamin D dose was increased
if a patient’s iPTH was 300 pg/ml despite reaching the maximum
cinacalcet dose or in the event of hypocalcemia not resolved with oral
calcium. Changes in phosphate binders were allowed according to the
algorithm.
iPTH >300 pg/ml
Begin Cinacalcet Treatment
iPTH
<150 pg/ml
iPTH = 150–300 pg/ml iPTH >300 pg/ml 
Despite Maximum 
Dose of Cinacalcet
Ca and P 
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Ca and P 
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High
Reduce Vit Da Maintain Reduce Dose of 
Vit D
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Figure 1. OPTIMA treatment algorithm. When indicated, the
dose of a vitamin D (vit D) sterol was reduced by approxi-
mately 50% in sequential steps until a minimum administered
dose was reached: intravenous calcitriol, 0.5 g three times per
week (TIW); intravenous alfacalcidol, 1 g TIW; intravenous
paracalcitol, 2 g TIW; oral calcitriol, 0.25 g TIW; oral alfacal-
cidol, 0.25 g/d. aThe dose of cinacalcet was reduced if a
patient was not receiving vitamin D.
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Biochemical Determinations
Plasma PTH and serum calcium and phosphorus levels were mea-
sured at local laboratories at 2-wk intervals throughout the dose opti-
mization and efficacy assessment phases (weeks 1 to 19). A final as-
sessment was made at the final study visit of the efficacy assessment
phase (week 23). All sites were instructed to use the same type of PTH
assay throughout the course of the study.
Study End Points
The primary end point was the proportion of patients with mean
iPTH 300 pg/ml (31.8 pmol/L) during the efficacy assessment phase.
Secondary end points included the proportions of patients with both
mean Ca  P 55 mg2/dl2 (4.44 mmol2/L2) and iPTH 300 pg/ml;
mean Ca  P 55 mg2/dl2; mean calcium 9.5 mg/dl (2.37 mmol/L);
and mean phosphorus 5.5 mg/dl (1.78 mmol/L).
Patient-Reported Outcomes
Patient-reported outcomes were assessed at screening and at the end
of each study phase (weeks 15 and 23), using the EQ-5D and
KDQOL-SF quality of life questionnaires (27,28).
Statistical Analyses
The primary analyses of the efficacy end points were based on the
full analysis set, comprising all randomized patients. The propor-
tions of patients in the two treatment groups achieving the various
end points were compared using the Cochran-Mantel-Haenszel test
(stratified for baseline Ca  P and baseline vitamin D use). The
means of the biochemical parameters (PTH, calcium, and phospho-
rus) during the 7-wk efficacy assessment period were used to eval-
uate efficacy. PTH levels measured with the bio-intact assay were
multiplied by 1.95 for conversion to iPTH values (29). A last value
carried forward method was used for patients who did not have
laboratory values measured during the efficacy assessment period.
The patient-reported outcomes were compared between the two
treatment groups at each measurement point using the t test. The
safety analysis included any randomized patient who had received
at least one dose of cinacalcet or, if in the conventional care group,
who had at least one postscreening visit.
Results
Patients
A total of 552 patients at 111 centers across Europe were
enrolled, of whom 368 were randomized to receive cinacalcet
and 184 to receive conventional care. Demographic charac-
teristics and baseline laboratory values were adequately bal-
anced between treatment groups (Table 1). Approximately
two-thirds of patients in each group were receiving vitamin
Table 1. Patient demographics and baseline laboratory values
Characteristica Conventional Care (n  184) Cinacalcet (n  368)
Sex, n (%)
male 117 (64) 224 (61)
female 67 (36) 144 (39)
Race, n (%)b
white 172 (93) 349 (95)
black and other 12 (7) 14 (3)
Age, years
mean (SD) 58.3 (14.5) 58.5 (14.5)
range 24 to 84 20 to 89
Duration of dialysis, months mean (SD) 69.4 (73.6) 64.1 (72.1)
Dialysis type, n (%)
hemodialysis 151 (82) 285 (77)
hemodiafiltration 28 (15) 59 (16)
hemofiltration 0 3 (1)
peritoneal dialysis 5 (3) 21 (6)
Vitamin D use, n (%) 126 (68) 252 (68)
Phosphate binder use, % 90 92
calcium-based 41 48
sevelamer HCl 54 52
aluminum-based 20 19
iPTH, mean (SD), pg/ml 507 (143) 505 (147)
Ca  P, mean (SD) mg2/dl2 52.5 (15.4) 53.6 (16.4)
55 mg2/dl2, n (%) 113 (61) 227 (62)
55 mg2/dl2, n (%) 71 (39) 141 (38)
Serum calcium, mean (SD), mg/dl 9.7 (0.8) 9.7 (0.8)
Serum phosphorus, mean (SD), mg/dl 5.4 (1.5) 5.5 (1.7)
aNo statistically significant differences between the two groups in any baseline demographic or laboratory value
comparison.
bRace information was lacking for five patients in the cinacalcet group.
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D sterols at enrollment, and almost all were receiving phos-
phate binders, with little difference between groups in the
types of agents used. There were 340 patients (113 conven-
tional care; 227 cinacalcet) with Ca  P 55 mg2/dl2 and 212
patients (71 conventional care; 141 cinacalcet) with Ca  P
55 mg2/dl2. As a result of site errors during the enrollment
procedure, three patients (2%) in the conventional care group
and 1 patient (1%) in the cinacalcet group were within the
recommended KDOQI iPTH target range at study entry.
Five patients randomized to cinacalcet did not receive the
drug and two patients randomized to conventional care re-
ceived cinacalcet (as a result of administrative errors) for a
few days immediately after randomization. Each of these
patients was included in their assigned treatment group for
the efficacy analyses. For the safety analyses, these patients
were analyzed according to whether or not they had received
cinacalcet. In total, 82% of patients in the conventional care
group and 76% of those randomized to cinacalcet completed
the efficacy assessment phase. Reasons for early discontinu-
ation of study treatment included adverse events (1% con-
ventional care, 7% cinacalcet), withdrawal of consent (2%
conventional care; 4% cinacalcet), death (3% in each group),
kidney transplant (3% conventional care; 2% cinacalcet), and
other causes (7% conventional care; 5% cinacalcet).
Achievement of Target Levels for Biochemical Parameters
The percentages of patients achieving the targets and the
mean changes from baseline in PTH, Ca  P, calcium, and
phosphorus are summarized in Table 2 and Figure 2.
PTH
During the efficacy assessment phase, 71% of cinacalcet-
treated patients achieved an iPTH level 300 pg/ml (Table
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Figure 3. Mean (SE) iPTH over time. Error bars represent 1 SE;
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Figure 4. Mean Ca  P over time. Ca  P: 1 mmol2/L2 
1 mg2/dl2  0.08; B: baseline.
Table 2. Achievement of PTH, Ca  P, calcium, and phosphorus targets
Parameter
Percentage (%) of Patients Achieving Targeta
Conventional Care, % (n  184) Cinacalcet, % (n  368) Cinacalcet Efficacy Assessment
Phase versus Conventional Care
Efficacy Assessment Phase
Statistical Comparison (P Value)Baseline
Efficacy Assessment
Phase Baseline
Efficacy Assessment
Phase
iPTH 2 22 1 71 0.001
Ca  P 59 58 60 77 0.001
iPTH and Ca  P 0 16 0 59 0.001
Calcium 43 33 45 76 0.001
Phosphorus 56 50 56 63 0.002
aiPTH 300 pg/ml, calcium 9.5 mg/dl, and phosphorus 5.5 mg/dl.
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2), 82% achieved an iPTH 300 pg/ml or a 30% reduction
from baseline and 54% achieved an iPTH level in the range
150 to 300 pg/ml. The corresponding proportions of
patients achieving these targets in the conventional care
group were 22%, 28%, and 17%, respectively. Mean iPTH
decreased by 46% in the cinacalcet group (from 505 pg/ml at
baseline to 264 pg/ml during the efficacy assessment phase).
In the conventional care group, iPTH increased from 507
pg/ml at baseline to 519 pg/ml during the efficacy assess-
ment phase (Table 3; Figure 3). A total of nine assays were
used across sites (data available for 85 sites); the majority of
sites (78%) used one of three types of assay, the Immulite
2000-intact PTH (Diagnostics Product Corporation, Los An-
geles, CA), Intact PTH Advantage (Nichols Institute, San
Clemente, CA), or the Elecsys PTH (Roche Diagnostics, In-
dianapolis, IN) assay. The proportion of patients using the
three assays was similar for both treatment groups (204/246
patients (83%) in the cinacalcet group and 135/177 (76%) in
the conventional therapy group).
Ca  P
A greater proportion of patients in the cinacalcet group
achieved Ca  P 55 mg2/dl2, compared with conventional
care (77% versus 58%, respectively; P  0.001; Table 2). The
mean Ca  P decreased by 12% in the cinacalcet group (from
53.6 mg2/dl2 to 45.7 mg2/dl2), but increased by 5% in the
conventional care group (Table 3; Figure 4).
PTH and Ca  P
A higher proportion of patients in the cinacalcet group
achieved target values of both PTH and Ca  P simultaneously
compared with in the conventional care group (59% versus 16%,
respectively; P  0.001; Table 2).
Serum Calcium
During the efficacy assessment phase, 76% of cinacalcet-
treated patients versus 33% of conventional care patients
achieved Ca levels 9.5 mg/dl (P  0.001; Table 2). Mean
serum calcium decreased by 7% in the cinacalcet group but
showed little change in patients receiving conventional care
(Table 3).
Serum Phosphorus
The proportion of patients achieving the targeted phosphorus
level (5.5 mg/dl) was also higher in the cinacalcet group than
in the conventional care group (63% versus 50%; P  0.002;
Table 2).
Efficacy by Severity of Disease
Baseline PTH
Among patients treated with cinacalcet, 80% of those with a
baseline iPTH level of 300 to 500 pg/ml and 63% of those with
a baseline iPTH 500 to 800 pg/ml achieved the iPTH target
(Figure 5a). Patients with a mean baseline iPTH level of 700 to
800 pg/ml achieved a mean iPTH level above the KDOQI range
(362 pg/ml), however, this still represented a mean decrease of
52% from baseline. (Figure 5b). Similarly, 64% of cinacalcet
patients with a baseline iPTH level of 300 to 500 pg/ml group
achieved both PTH and Ca  P targets simultaneously, com-
pared with 54% of those with a baseline iPTH level of 500 to 800
pg/ml (Figure 5a).
Baseline Ca  P
For cinacalcet-treated patients whose baseline Ca  P was
55 mg/dl, the mean (SD) changes in phosphorus and Ca  P
were 14% (1.8) and 20% (1.9), respectively. In total, 90% of
the cinacalcet-treated patients whose baseline Ca  P was
55 mg2/dl2 maintained control of Ca  P, compared with
74% of patients in the conventional care group. In the cinacalcet
group 55% of patients with a baseline Ca  P 55 mg2/dl2
achieved control of Ca  P in the efficacy assessment period,
compared with 31% in the conventional care group.
Cinacalcet Use
The most common cinacalcet doses, used by 65% of patients,
were 60 mg/d or less. A total of 6% of patients used the
maximum 180-mg/d dose most often versus other dosages
Table 3. Mean iPTH, Ca  P, and serum calcium and phosphorus levels at baseline and during the efficacy
assessment phase
Characteristic Conventional care, Mean (SD) (n  184) Cinacalcet, Mean (SD) (n  368)
iPTH (pg/ml)
baseline 507 (143) 505 (147)
efficacy assessment phase 519 (281) 264 (168)
Ca  P (mg2/dl2)
baseline 52.5 (15.4) 53.6 (16.4)
efficacy assessment phase 53.0 (14.7) 45.7 (14.9)
Calcium (mg/dl)
baseline 9.7 (0.8) 9.7 (0.8)
efficacy assessment phase 9.8 (0.7) 9.0 (0.8)
Phosphorus (mg/dl)
baseline 5.4 (1.5) 5.5 (1.7)
efficacy assessment phase 5.4 (1.5) 5.1 (1.6)
iPTH: 1 mmol/L  1 mg/dl  0.105; Ca  P: 1 mmol2/L2  1 mg2/dl2  0.08; calcium: 1 mmol/L  1 mg/dl  0.25;
phosphorus: 1 mmol/L  1 mg/dl  0.323.
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throughout the efficacy assessment phase. The mean and me-
dian doses were 56 mg/d and 30 mg/d, respectively. Lower
doses of cinacalcet were needed to control PTH in patients with
less severe disease (median daily dose of 30 mg in patients with
baseline PTH 300 to 500 pg/ml and 60 mg in those with
baseline PTH 500 to 800 pg/ml).
Changes in Vitamin D, Phosphate Binder, and Dialysate
Calcium Use
The proportion of patients receiving vitamin D sterols in-
creased from 66% to 81% at the end of the study in the con-
ventional care group and from 68% to 73% in the cinacalcet
group. Because of the different vitamin D analogs received by
patients, direct comparisons of dosages administered in the two
treatment groups are difficult. Nevertheless, by converting each
dose received into a multiple of the protocol-defined minimum
dose for a particular analog, it was possible to define a relative
dose for comparative purposes (Table 4). Overall, there was a
small change in the vitamin D relative dose in both treatment
groups (14% increase in conventional care patients; 6% decrease
in cinacalcet patients). However, as the OPTIMA algorithm
specifically recommended increasing or decreasing the vitamin
D dose depending upon the patient’s condition, a larger differ-
ence occurred in those patients who were receiving vitamin D
at baseline. In this subpopulation the mean relative dose de-
creased by 22% in cinacalcet-treated patients, but increased by
3% in conventional care patients (Table 4). In patients who were
receiving vitamin D and who had Ca  P 55 mg2/dl2 at
baseline, the mean relative dose of vitamin D decreased by 51%
in cinacalcet-treated patients, but increased by 8% in the con-
ventional care group.
The proportion of patients taking calcium-containing phos-
phate binders or calcium supplements remained essentially
unchanged throughout the study in the conventional care
group (approximately 42% of patients), but increased from 48%
to 74% in cinacalcet patients. However, for those receiving
calcium-containing binders or calcium supplements, the mean
daily oral dose of elemental calcium remained relatively con-
stant throughout the study in both treatment groups (2.2 g/d in
cinacalcet patients and 2.1 g/d in conventional care patients at
week 23). The proportion of patients receiving sevelamer-based
binders during the study decreased from 52% to 48% in the
cinacalcet group but increased from 54% to 60% in the conven-
tional care group. Similarly, use of aluminum-based binders
decreased from 19% to 12% in cinacalcet patients but increased
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Figure 5. A, Patients (%) achieving end points by baseline iPTH
levels. B, Reduction in PTH based on PTH levels at baseline.
Table 4. Relative dose of vitamin Da
Conventional Careb (n  123) Cinacalcet (n  252)
Baseline End of Study Baseline End of Study
Mean (SD) 2.6 (2.3) 2.7 (2.2) 2.2 (1.6) 1.7 (1.6)
Median (Q1, Q3) 2.0 (1.0, 4.0) 2.0 (1.5, 4.0) 2.0 (1.0, 2.7) 1.1 (0.5, 2.3)
% Change in mean 3% 22%
aOnly those patients receiving a vitamin D sterol at baseline are included. Minimum doses of vitamin D sterols were
defined as follows: iv calcitriol, 0.5 g TIW; iv alfacalcidol, 1 g TIW; iv paracalcitol, 2 g TIW; oral calcitriol, 0.25 g TIW;
oral alfacalcidol, 0.25 g/d.
Relative dose: Because of the multiple vitamin D analogs allowed in this study, dosage comparisons were based on
conversion of each dose a patient received into a multiple of the defined minimum dose for a particular sterol. For example, if
a patient received 1 g iv calcitriol TIW, for which the minimum dose is 0.5 g TIW, then the relative dose was calculated to
be 2.
bThe mean relative dose of vitamin D (SD) at week 23 in patients not receiving vitamin D at the start of study was 1.28
(SD 1.01) (n  33).
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marginally for conventional care patients (20% to 21%). In those
patients treated with sevelamer at week 23, the mean dose was
5 g/d in the conventional care group compared with 4.5 g/d in
the cinacalcet group. Although the overall mean doses of vita-
min D and phosphate binders remained relatively stable, there
were substantial changes in the use of these drugs in individual
patients receiving conventional care; ie 51% of patients either
started vitamin D or had their dose increased, whereas 43%
decreased or stopped vitamin D at some point during the
study. In addition, almost half of patients who received calci-
um-containing phosphate binders or sevelamer in the conven-
tional care group had a change in their dosage.
The mean (SD) dialysate calcium concentration remained
relatively stable in both treatment groups (cinacalcet group:
2.7 (0.5) mEq/L at baseline, 2.9 (0.5) mEq/L at week 23; con-
ventional care group: 2.7 (0.5) mEq/L at baseline, 2.6 (0.5)
mEq/L at week 23).
Patient-Reported Outcomes
The mean (SD) EQ-5D utility index score and KDQOL-SF scale
scores at baseline were similar in both treatment groups and
remained essentially unchanged in each group throughout the
study.
Safety Analysis
A total of 80% of cinacalcet patients and 59% of conventional
care patients experienced at least one adverse event (Table 5).
The most common adverse events were mild to moderate nau-
sea and vomiting, both of which were reported more frequently
in the cinacalcet group than in the conventional care group
(nausea 32% versus 3%; vomiting 24% versus 7%). In total, 3% of
patients discontinued cinacalcet use because of nausea and 2%
because of vomiting. Diarrhea was also more common in the
cinacalcet group (13% versus 7%). Three percent of patients in
the two treatment groups died during or within 30 d of discon-
tinuation of causes consistent with those commonly seen in this
patient population. The most common causes of death were
myocardial infarction (one conventional care patient, two cina-
calcet patients) and sudden cardiac death (one patient in each
treatment group). Other causes of death were single events.
Hypocalcemia (serum calcium 7.5 mg/dl on at least two
consecutive measurements during the study) occurred in 5% of
patients receiving cinacalcet and 1% of patients receiving con-
ventional care.
Discussion
The KDOQI guidelines for the management of bone metabo-
lism and disease in CKD are evidence-based treatment recom-
mendations that aim to reduce the risk of vascular calcification
and bone disease through the control of biochemical parame-
ters. Cinacalcet is unique in its ability to simultaneously lower
PTH, calcium, phosphorus, and Ca  P in patients with SHPT
and thus could become an important component in treatment
regimens for this disease. The OPTIMA treatment algorithm
was designed to be a practical treatment paradigm that builds
upon the properties of cinacalcet by increasing or decreasing
vitamin D dosage to increase the achievement of treatment
targets. Achieving control of PTH, calcium, and phosphorus
levels with conventional treatment in CKD patients with SHPT
presents a considerable challenge. This was well illustrated by
the Dialysis Outcomes and Practice Patterns Study (DOPPS II).
Of approximately 4000 patients on hemodialysis, only 26.2%
had mean iPTH values within the KDOQI target range of 150 to
300 pg/ml (30). In our study, despite the best efforts of inves-
tigators and more stringent monitoring of patients (as required
by the study protocol) compared with clinical practice, only
22% of patients receiving conventional care achieved the iPTH
target, with no change in the proportion of patients reaching
the Ca  P target range. This might at least in part reflect the
fact that the patients enrolled in the study had reached the
limits of conventional treatment, with limited additional op-
tions for the control of SHPT in those in the conventional
treatment group. Indeed, in the 27% of patients in the conven-
tional group who did not receive vitamin D at the start of the
study, but did so after the study began, the mean relative dose
was low (1.28), which suggests it was not possible to aggres-
sively use vitamin D in this group of patients. Furthermore, the
deliberate lack of uniformity in the treatment that the conven-
tional care patients received possibly enhanced the superiority
of cinacalcet treatment.
Application of the cinacalcet-based OPTIMA treatment algo-
rithm resulted in significant reductions in mean iPTH values,
with 71% of patients achieving the primary end point of a mean
iPTH value 300 pg/ml and 82% achieving either mean iPTH
300 pg/ml or a 30% mean reduction from baseline. Thus,
the addition of cinacalcet to vitamin D therapy results in addi-
tional control of iPTH in patients with SHPT who previously
failed treatment with vitamin D alone. The decrease in iPTH
values affected by cinacalcet was accompanied by reductions in
mean Ca  P, calcium, and phosphorus levels consistent with
previous studies (23–26). These parameters remained essen-
tially unchanged among patients receiving only conventional
care. In reporting these highly encouraging data, we should
acknowledge a paper by Souberbielle et al. (31), which has
shown marked variation in iPTH measurement readings using
Table 5. Summary of adverse events
Conventional Care, %
(n  182)
Cinacalcet, %
(n  365)
All adverse events 59 80
Most common adverse
events (5%)
Nausea 3 32a
Vomiting 7 24a
Diarrhea 7 13b
Nasopharyngitis 3 7
Muscle cramp 3 7
Dyspepsia 2 5
Headache 2 5
Pruritus 2 5
aP  0.001 versus conventional care.
bP  0.05 versus conventional care.
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different assays. In this study, most sites used one of three
different types of assay, and this was balanced across treatment
arms; therefore, the reported degree of change for PTH from
baseline to the end of the study may be presumed to be reliable.
Another potential influence on our findings might result from
site effects whereby imbalances in the distribution of patients
by treatment group between centers affects study results. How-
ever, our analyses showed that the majority of sites (89/111 or
80%) recruited six or fewer patients, and only 2/111 sites re-
cruited 15 patients. Although the randomization was not
stratified by site, 98 of the 111 sites (88%) or 83% of patients had
treatment allocations that were consistent with a randomization
stratified by site. It was not feasible to perform an analysis
adjusting for site because interpretation would have been dif-
ficult with so many small centers.
In the majority of previous studies that evaluated cinacalcet
in patients with SHPT, alteration of vitamin D dosage was
permitted only on the grounds of patient safety (24–26). In one
2-yr cinacalcet study, investigators were permitted to adjust the
dose or type of vitamin D sterol used to mimic normal clinical
practice (32). The results from this long-term study by Moe et al.
showed no significant change in either the proportion of pa-
tients receiving vitamin D sterols or phosphate-binding agents,
or in the doses of either. In our study, with doses of cinacalcet,
vitamin D sterols, and phosphate-binding agents optimized
according to the OPTIMA algorithm, the mean relative dose of
vitamin D sterols decreased by 22% in patients who were using
vitamin D treatment to control their PTH. In the subset of
patients with Ca  P 55 mg2/dl2 where the utility of vitamin
D had reached its limit, the OPTIMA algorithm enabled a 51%
reduction of vitamin D usage with comparable or greater re-
duction of PTH and Ca  P, compared with the overall cina-
calcet study population (Figure 2). The combination of cinacal-
cet plus decreased vitamin D enabled a 14% reduction in
phosphorus levels and a 20% reduction in Ca P levels in these
patients, suggesting the efficacy of this therapeutic strategy.
In accordance with the current clinical practices of reserving
novel therapies for patients with more severe disease, cinacal-
cet is currently most often used in SHPT patients with severely
uncontrolled PTH or in those with Ca  P 55 mg2/dl2.
Although patients with a high PTH level might be expected to
be less likely to achieve treatment targets, the significant and
simultaneous reductions in PTH and Ca  P levels observed in
this study indicate the potential for major clinical benefits in
terms of improved disease control in these patients. We did
find that patients with less severe disease (iPTH between 300 to
500 pg/ml) were more likely to achieve study targets than those
with higher baseline iPTH levels, and the dose of cinacalcet
required to achieve the recommended targets was lower in
patients with less severe disease. This suggests that treatment
of SHPT with cinacalcet in earlier, less severe disease stages
may be more cost effective, although appropriate analyses are
needed to confirm this supposition. The long-term benefits, if
any, of commencing cinacalcet treatment early in the course of
SHPT remain to be determined, but earlier and sustained
achievements of KDOQI targets might result in improved clin-
ical outcomes for patients.
There were no unexpected safety findings from tolerability
data in the cinacalcet group compared with previous studies
(24–26,32). This study’s open-label design may have led to an
unplanned bias that contributed to an underreporting of nausea
and vomiting in the conventional care group, resulting in the
lower than expected incidences of these events observed in
these patients.
In summary, this study was the first trial to directly compare
the efficacy of cinacalcet with unrestricted conventional care.
Whereas it is possible that the efficacy of cinacalcet relative to
conventional treatment may have been enhanced by the inclu-
sion of patients who had reached the limits of conventional
therapy, our data show superior efficacy for the cinacalcet-
based treatment algorithm in achieving the stringent key met-
abolic targets for patients with SHPT. Furthermore, cinacalcet
allowed the attainment of these targets with a lower dose of
vitamin D sterols.
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